Mastoparan, a peptide toxin from wasp venom, stimulates glycogenolysis mediated by an increase of the cytosolic free Ca2+ concentration but not by an increase of cAMP in rat hepatocytes  by Tohkin, Masahiro et al.
Volume 260, number 2, 179-182 FEB 08040 January 1990 
Mastoparan, a peptide toxin from wasp venom, stimulates glycogenolysis 
mediated by an increase of the cytosolic free Ca2+ concentration but not 
by an increase of CAMP in rat hepatocytes 
Masahiro Tohkin, Tatsurou Yagami and Takashi Matsubara 
Shionogi Research Laboratories, Shionogi and Co. Ltd., Fukushima-ku, Osaka 553, Japan 
Received 30 November 1989 
A wasp venom, mastoparan, rapidly increased the cytosolic free Ca2+ concentration ([Ca”],) and activated phosphorylase in rat hepatocytes in 
a concentration-dependent manner. Mastoparan could increase [Caz’], even in the absence of extracellular Ca 2+ but a larger increase was observed , 
in the presence of extracellular Ca *+. 2+ Thus, mastoparan mobilized Ca from intracellular and extracellular Caz+ stores. It also activated inositol 
triphosphate (IP,) accumulation, but did not stimulate CAMP production. From these results, we conclude that mastoparan activates rat hepatic 
glycogenolysis mediated by the accumulation of IP,, which causes an increase of [Ca2+], but not that mediated by CAMP. 
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1. INTRODUCTION 
Mastoparan, a tetradecapeptide purified from wasp 
venom [ 11, is a potent stimulator of exocytosis from 
various endocrine tissues. It can cause secretion of 
histamine from mast cells, serotonin from platelets, 
catecholamines from chromaffin cells, and prolactin 
from the anterior pituitary [2,3]. Okano et al. reported 
that these effects of mastoparan are mediated by an in- 
crease in the cytosolic free Ca2+ concentration ([Ca2+]i) 
that is triggered with the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) by the 
PIPz-specific phospholipase C in the plasma membrane 
[4]. Subsequent studies by Higashijima et al. clarified 
that the activation of phospholipase C by mastoparan 
is mediated by direct activation of guanine nucleotide 
binding protein (G-protein), which is coupled with 
phospholipase C [5]. 
Rat hepatic glycogenolysis is known to be activated 
by adrenergic agonists or glucagon. Epinephrine which 
acts via an ai-adrenergic receptor increases [Ca2’]i and 
activates hepatic glycogenolysis, while glucagon in- 
creases the CAMP content followed by activation of 
glycogenolysis [6,7]. In both cases, G-proteins are in- 
volved in these signal transduction systems, but a dif- 
ferent subtype of G-protein is coupled with each 
effector system, i.e. glucagon receptors are coupled 
with G,-protein, which stimulates adenylate cyclase, 
and cui-adrenergic receptors are coupled with an 
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unknown G-protein(s) which stimulates phospholipase 
C [6-81. In the present study, we compared the effect 
of mastoparan on [Ca2’]i and adenylate cyclase in in- 
tact liver cells and found evidence that mastoparan ac- 
tivates rat hepatic glycogenolysis mediated by the’ 
increase of [Ca’+]i but not that mediated by CAMP. 
2. MATERIALS AND METHODS 
2.1. Materials 
Sic Wistar rats (9-11 weeks old) were obtained from Japan SLC 
(Hamamatsu, Japan). Mastoparan was purchased from Peptide In- 
stitute (Minoh, Japan) and islet-activating protein, pertussis toxin, 
was from Kaken Seiyaku K.K. (Kyoto, Japan). L-myo-[3H]inositol 
(3.02 TBq/mmol) was obtained from Amersham, the anion exchange 
resin AC 1 x 8 (formate form, 100-200 mesh) was from Bio-Rad, and 
the CAMP assay kit was from Yamasa Shoyu K.K. (Choshi, Japan). 
All other chemicals have been described previously [9]. 
2.2. Isolation of rat hepatocytes and measurement of [Co”]i, 
phosphorylase activity, and CAMP content 
Rat hepatocytes were isolated from male Sic Wistar rats by the col- 
lagenase perfusion method as described elsewhere [9]. Measurements 
of phosphorylase activity and [Ca”]i in rat hepatocytes were also 
described previously 191. To measure their CAMP contents, the 
hepatocytes were preincubated with 0.5 mM isobutylmethylxanthine 
in Hepes buffer medium (134 mM NaCl, 4.7 mM KCl, 1.2 mM 
KHzPO~, 1.2 mM MgS04, 1.3 mM CaCl2, 5 mM NaHCOs, 40 mM 
glucose, and 10 mM N-2-hydroxyethyl piperazine-iV’-2-ethane 
sulfonic acid, pH 7.4) for 15 min at 37°C under an atmosphere of 
95% Or-5% CO2 [lo]. The preincubated hepatocytes were then in- 
cubated with mastoparan for 2 min and the reactions were stopped 
by the addition of 0.1 N HCl (final concentration). The hepatocytes 
were homogenized and centrifuged. The resulting supernatant was 
collected and the CAMP content was measured with a radioim- 
munoassay kit. 
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2.3. Measurement of inositol phosphate metabolism in hepatocytes 
Hepatocytes were suspended at 3 x lo6 cells/ml in Hepes buffer 
medium containing 0.1% bovine serum albumin and 370 kBq/ml 
myo-[3H]inositol. Incubations were carried out at 37°C under an at- 
mosphere of 95% Oz-5% CO2 maintained by continuous gassing for 
90 min [ill. The cells were subsequently washed three times to 
remove excess [‘Hlinositol. When the inositol phosphate metabolism 
in the intact hepatocytes was measured, [3H]inositol-labeled 
hepatocytes were preincubated in Hepes buffer medium containing 
10 mM LiCl for 10 min at 37°C and the reaction was initiated by ad- 
ding mastoparan. To elucidate the inositol phosphate metabolism in 
the plasma membrane, prelabeled hepatocytes were homogenized in 
HEA buffer (50 mM N-2-hydroxyethyl piperazine- 
N ‘-Zethanesulfonic acid, 1 mM ethylene glycol-bis(&aminoethyl 
ether) N, N, N ‘, N ‘-tetraacetic acid and 50 kallikrein units/ml 
aprotinin, pH 7.4) and centrifuged at 1000 x g for 5 min to remove 
unbroken cells and nuclei. The resulting supernatant was centrifuged 
at 10000 x g for 15 min, and the resulting pellets were resuspended 
in HEA buffer (same volume as homogenization) and used as the 
plasma membrane fractions. This suspension was preincubated with 
10 mM LiCl, 6 mM MgClz, and 500 nM Ca*+ at 37°C for 5 min, and 
the reaction was initiated by the addition of mastoparan and 500 nM 
of GTP-7-S. After incubation of the plasma membrane for 5 min or 
for the indicated incubation time in the case of hepatocytes kept at 
37”C, the reactions were stopped by adding an equal volume of 15% 
trichloroacetic acid. The resulting supernatant was washed with 
diethylether 5 times and neutralized with 50 mM sodium borate. In- 
ositol phosphates in the solution were separated on an AC 1 x 8 col- 
umn (formate form) as described previously [12]. 
2.4. ADP-ribosylation of liver plasma membranes by IAP 
Rough liver plasma membranes prepared as described in section 
2.3 were resuspended in HEA buffer containing 10 mM thymidine 
and 1 mM NAD at 0.5 mg protein/ml, and ADP ribosylation of this 
plasma membrane was initiated by addition of 2 fig/ml of activated 
islet-activating protein (IAP) and incubated at 37°C for 30 min. 
After the incubation, the membrane suspensions were centrifuged at 
10000 x g for 15 min and the pellets were resuspended in HEA buf- 
fer. This centrifugation process was repeated 3 times to remove IAP 
and NAD. No significant [32P]ADP-ribose incorporation into the LY- 
subunits of IAP-sensitive G-proteins were observed when the IAP- 
pretreated liver plasma membrane was ADP-ribosyiated by IAP 
again using [32P]NAD according to the method of Katada [13]. 
3. RESULTS AND DISCUSSION 
Increases in phosphorylase activity and [Ca2+]i were 
detected in isolated hepatocytes by the addition of 
various concentrations of mastoparan, with the pat- 
terns indicating that the relationship between these 
changes and mastoparan concentrations were almost 
the same (fig.1). We could also observe the glucose out- 
put by mastoparan in isolated perfused rat liver (data 
not shown). The time course changes of the 
mastoparan-induced increase in [Ca2+]i were compared 
with those of epinephrine. As shown in fig.2, 
epinephrine transiently increased [Ca2+]i, which then 
rapidly returned to the resting level. With mastoparan, 
the increase in [Ca2’]i occurred but no return of the 
[Ca2+]i level was observed (fig.2). This result indicated 
that mastoparan-stimulated intracellular Ca2+ 
mobilization was slightly different from the receptor- 
operated mechanism and there are two possibilities: (i) 
mastoparan continuously activates G-protein(s); and 
(ii) mastoparan cannot activate the Ca2+ exclusion 
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Fig. 1. Concentration-dependent enhancement of phosphorylase 
activity and increase in [Ca’+]i by mastoparan. Isolated rat 
hepatocytes were incubated with the indicated concentrations of 
mastoparan at 37”C, and phosphorylase activities (open circles) were 
measured 2 min after mastoparan treatment. For the determination 
of [Ca’+],, fura-2-loaded hepatocytes were incubated at 37°C with 
the indicated concentrations of mastoparan and changes of [Ca”]i 
were determined (closed circles). Basal [Ca”], was 294 + 70 nM 
(mean f SE). 
system. A mastoparan-stimulated increase of [Ca2+]i 
was observed even in the Ca2+-free incubation medium. 
When Ca2+ (final concentration of 1.3 mM) was added 
to the Ca2+-free incubation buffer after the treatment 
with mastoparan, a further increase of [Ca2+]i was 
detected as shown in fig.3. These results indicate that 
mastoparan caused a release of Ca2+ from the in- 
tracellular store and an influx of extracellular Ca2+. 
The increase of [Ca2+]i by receptor activation is 
known to be triggered by the hydrolysis of PIP2 in the 
plasma membrane [14]. Then, we examined the effect 
of mastoparan on the phosphatidyl inositide 
metabolism in the rat hepatic plasma membrane. Fig.4 
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Fig.2. Time course changes of [Ca*‘]i induced by epinephrine (A) or 
mastoparan (B). Fura-2-loaded rat hepatocytes were incubated at 
37°C in the incubation medium containing 1.3 mM Ca*+ and the 
changes of fluorescence intensities were detected after addition of 
10pM epinephrine (A) or 50pM mastoparan (B). Epinephrine and 
mastoparan were added at time 0 in the figure. 
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Fig.3. Epinephrine (A) or mastoparan (B) induced an increase in 
lCa2+l, in the absence of extracellular Ca”. Fura-2-loaded 
hepatocytes were washed out 3 times with Ca*+-free buffer, and 
incubated in Ca*‘-free buffer at 37°C. 10pM epinephrine (A) or 
50 /tM mastoparan (B) were added to the incubation medium at time 
0 (a) and 1.3 mM CaClr (final concentration) was added to the 
incubation medium at 2.5 min (b). 
shows the time course of the accumulation of inositol 
triphosphate (IP3), indicating that 50 ,uM of 
mastoparan caused IP3 production, reaching about 
8-fold the control level in isolated hepatocytes. The 
maximal rate of IP3 production was observed within 
1 min and during this period, the increase of [Ca2+]i 
was also maximal (fig.2). IP3 production by 
mastoparan was also observed in a cell-free system 
(fig.5). These results show that mastoparan stimulated 
the increase of [Ca2+]i associated with PIP2 hydrolysis 
in liver plasma membrane followed by activation of 
hepatic glycogenolysis. 
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Fig.4. Mastoparan-stimulated IPs production. isolated rat 
hepatocytes, prelabeled with [‘Hlinositol as described in section 2, 
were incubated with mastoparan for the indicated periods of time, 
and the reaction was terminated by adding an equal volume of 
trichloroacetic acid. Inositol phosphates were separated and detected 
Control 1.97 3.67 
Mastoparan (50 CM) 3.71 4.13 
Glucagon (1 nM) 3.43 7.34 
Glucagon (I PM) 6.24 82.5 
Isolated rat hepatocytes were incubated with 50 PM mastoparan and 
1 nM or 1 pM glucagon for 2 min at 37°C. When measuring CAMP 
content, 0.5 mM isobutylmethylxanthine was added to the 
incubation buffer. The phosphorylase activity and CAMP content in 
as described in section 2. the hepatocytes were measured as described in section 2. 
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Fig.5. Effect of IAP on mastoparan-stimulated IPr accumulation. 
Rat liver plasma membranes prepared from [3H]inositol-prelabeled 
hepatocytes were treated with (closed circles) or without (open circles) 
IAP as described in section 2. The plasma membranes were incubated 
with 500 nM GTP-r-S, 500 nM Ca*+ and the indicated 
concentrations of mastoparan for 5 min at 37°C. IPa was measured 
as given in fig.4. 
IAP Treated 
Higashijima et al. showed that mastoparan 
stimulated the steady state level of GTP hydrolysis by 
G-proteins and this effect had a selectivity for different 
types of G-proteins using purified G-proteins [5]. In rat 
hepatocytes, the ai-adrenergic receptor is coupled with 
unknown G-protein(s) which stimulates PIPz-specific 
phospholipase C, while the glucagon receptor is coupl- 
ed with G,-protein which stimulates adenylate cyclase 
[6-81. Therefore, we compared the effect of 
mastoparan on G, protein and G-protein coupled with 
phospholipase C in intact rat hepatocytes. Although 
50 ,uM of mastoparan and 1 nM of glucagon stimulated 
phosphorylase activity at the same level, an increase in 
CAMP was observed only on addition of glucagon 
(table 1). This finding indicates that mastoparan could 
Table 1 
Effects of mastoparan or glucagon on phosphorylase activity and 
CAMP accumulation 
Treatment Phosphorylase activity CAMP accumulation 
(units/lo* cells) (pmol/105 cells) 
181 
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not stimulate G,-protein, although it probably acts on 
the phospholipase C-coupled G-proteins. Higashijima 
et al. also suggested that IAP, pertussis toxin, inhibits 
the mastoparan-stimulated GTP-y-S binding activity of 
G-proteins [5]. And so, the effect of IAP on 
mastoparan stimulating IP3 accumulation in liver 
plasma membranes was then examined to obtain fur- 
ther information about the type of G-protein (fig.5). 
Mastoparan stimulated IP3 accumulation in the plasma 
membrane in a concentration-dependent manner, but 
IAP did not inhibit mastoparan-stimulated IP3 ac- 
cumulation. We recently observed that G-protein(s) 
coupled with ai-adrenergic receptors is IAP sensitive 
(manuscript in preparation). We do not know why the 
sensitivity of IAP differs between ai-adrenergic 
receptor-coupled G-protein and mastoparan-sensitive 
G-protein(s), but speculate that it may be caused by 
IAP not being able to completely inhibit the GTP-7-S 
binding activity of G-protein [5]. Another possibility is 
the existence of different G-proteins which stimulate 
PIP2 hydrolysis but have different affinities for 
mastoparan. Fitzgerald et al. and Aiyar et al. have 
reported that liver G-protein coupled with vasopressin 
receptors is IAP insensitive [15,16], which offers sup- 
port to the above hypothesis. 
The present findings indicate that mastoparan can 
activate specific G-proteins in liver cells coupled with 
PIPz-specific phospholipase C and increase [Ca’+]i 
resulting in activation of the phosphorylase. This effect 
of mastoparan is not inhibited by IAP. 
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